Kimberly Gentile - 05 Jan 2025 Form 4 Insider Report for Biohaven Ltd. (BHVN)

Role
SVP, Clinical Operations
Signature
/s/ George Clark, Attorney-in-Fact
Issuer symbol
BHVN
Transactions as of
05 Jan 2025
Net transactions value
-$75,580
Form type
4
Filing time
07 Jan 2025, 20:50:52 UTC
Previous filing
04 Jan 2024
Next filing
07 Jan 2026
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BHVN Common Shares Options Exercise $0 +3,750 +3.9% $0.000000 99,719 05 Jan 2025 Direct
transaction BHVN Common Shares Tax liability $75,580 -1,956 -2% $38.64 97,763 05 Jan 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BHVN Stock Options (Right to buy) Award $0 +91,000 $0.000000 91,000 05 Jan 2025 Common Shares 91,000 $38.64 Direct F2
transaction BHVN Restricted Share Unit Award Award $0 +15,000 $0.000000 15,000 05 Jan 2025 Common Shares 15,000 Direct F3, F4, F5
transaction BHVN Restricted Share Unit Award Options Exercise $0 -3,750 -25% $0.000000 11,250 05 Jan 2025 Common Shares 3,750 Direct F3, F4, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 No shares were sold - these shares were withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted share units.
F2 The shares underlying this option vest in four equal installments on January 5, 2025, 2026, 2027 and 2028, subject to the Reporting Person's continuous service with the Issuer at each vesting date.
F3 Each restricted share unit represents the contingent right to receive one common share of the Issuer.
F4 The reporting person was granted 15,000 restricted share units on January 5, 2025, vesting in four equal installments on January 5, 2025, 2026, 2027 and 2028, subject to the reporting person's continued service with the Issuer at each vesting date.
F5 Not applicable.